FDA Approves Frontline Eltrombopag for Severe Aplastic Anemia

November 16, 2018 – The FDA has expanded the approval of eltrombopag in combination with standard immunosuppressive therapy (IST) to include newly diagnosed adult and pediatric patients 2 years and older with severe aplastic anemia (SAA), according to Novartis, the manufacturer of eltrombopag. The agency also granted the agent a breakthrough therapy designation as a counter measure for hematopoietic sub-syndrome of acute radiation … (leggi tutto)